Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 242152
                    [Title] => CAIs: Reaching optimal cholesterol goals
                    [Summary] => A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals.


Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East regional medical director of the Schering-Plough Research Institute, in a lecture during the joint annual convention of the Philippine Society of Hypertension and Philippine Lipid Society recently. 


                    [DatePublished] => 2004-03-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

SCHERING-PLOUGH RESEARCH INSTITUTE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 242152
                    [Title] => CAIs: Reaching optimal cholesterol goals
                    [Summary] => A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals.


Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East regional medical director of the Schering-Plough Research Institute, in a lecture during the joint annual convention of the Philippine Society of Hypertension and Philippine Lipid Society recently. 


                    [DatePublished] => 2004-03-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

CAIs: Reaching optimal cholesterol goals

March 11, 2004 - 12:00am

A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals. Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East...

Science and Environment

Lowering ‘LDL-C’ gets a boost with breakthrough drug

February 19, 2004 - 12:00am

A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. Ezetimibe, launched by Schering-Plough...

Science and Environment